TNMU Associate Professor Participated in the European Congress of Cardiologists for Heart Failure

On May 21-24, 2022, Sofiya Lypovetska, Associate Professor of the Department of First Emergency Medical Aid and Emergency Medical Treatment, took part in the European Congress of Cardiologists for Heart Failure, which took place in Madrid.

The program of the Congress has become a new important branch, which continues to fill the so-called “gaps in evidence” in the treatment of heart failure. Despite the fact that in 2021 new guidelines for the management of patients with heart failure (https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-and-Chronic-Heart-Failure) and restrictions related to COVID-19 were established, which suspended many studies, the Congress was a bright and innovative event.

Presentations of interventions for the treatment of heart failure included improved forms of cardioresynchronization therapy, modulation of heart rate, timely telemonitoring to prevent decompensation and early laboratory biomarkers – OMICs RNA for accurate risk stratification.

There have been many innovative surprises in the field of drug treatment: the expansion of indications for long-known drugs and the emergence of completely new ones with a high level of evidence. Thus, the intermediate results of DEFINE-HF and PRESERVED-HF trials have shown that the use of SGLT2 inhibitors has its advantages in symptomatic patients regardless of the level of the ejection fraction. In contrast, the macitentan, an endothelin receptor antagonist used in pulmonary hypertension, was negatively assessed in the SERENADE trials. It did more harm than good to patients with preserved ejection fraction and pulmonary vascular disease.

To reduce the level of decompensation of heart failure and, accordingly, hospitalizations requiring intravenous infusions of diuretics ESC has officially made it possible to use special furosemide patch-pumps for subcutaneous administration. In terms of bioavailability, efficacy and home use, these devices have significant advantages over intravenous drugs, as confirmed in the SUBCUT-HF trial.

According to the REDWOOD-HCM Open Label, the study confirmed the effectiveness of a new cytokinetic agent Aficamten in patients with obstructive hypertrophic cardiomyopathy. And for patients with reduced ejection fraction and hypotension, Omecamtiv mecarbil has been proposed, which improves myocardial contractility without lowering blood pressure. According to GALACTIC-HF trial, it significantly reduced cardiovascular mortality. Unfortunately, in the case of hypotension and renal dysfunction, the scope of our pharmacological agents is significantly limited, so the use of tropic therapy, namely selective activator of cardiac myosin has its prospects.

During the congress, Sofiya Lypovetska successfully presented a poster presentation.

The European Society of Cardiology is one of the first leading scientific communities in the world, which, despite its apolitical nature, has expressed support and solidarity with Ukraine, condemning Russia’s aggression. During the full-scale war, Russian and Belarusian scientists are banned from participating in all scientific activities and publications in ESC publications.

During the Congress in the Virtual case area, the Body Interact team, which are long-term partners of TNMU, presented interesting clinical cases that could be modelled independently. Body Interact, a world leader in simulation training, has also expressed its respect and support for Ukraine at this difficult time (photo 3 – Silvério de Sousa Mendes, CEO of Body Interact).